BioLife Solutions Announces Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
BioLife Solutions (BLFS) Tops Q4 EPS by 2c, Revenues Miss; Offers FY20 Revenue Guidance
March 11, 2020 4:32 PM EDTBioLife Solutions (NASDAQ: BLFS) reported Q4 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $9.01 million.
Mike Rice, BioLife CEO, commented, "2019 saw a remarkable transition for BioLife, as we transformed the business from a single product company to a multi-solution provider of class-defining bioproduction tools to the cell and gene therapy industry.
We posted record revenue of $27.4 million and record adjusted EBITDA of $5.7 million, driven by our 2019 acquisitions, which we believe confirms that our strategy to innovate and consolidate in this... More
